Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Dec 6, 2018 in Leukemia | 0 comments

In a nutshell

The study looked at the safety and effectiveness of ponatinib (Iclusig) in the treatment of chronic myeloid leukemia (CML). Researchers found that ponatinib was safe and effective in previously treated patients with CML.

Some background

Chronic myeloid leukemia is a type of cancer of the bone marrow. This can lead to abnormal immune cells. It is often treated with medications that target certain proteins on cancer cells. Ponatinib is a drug that works in this way. It is important to research the safety and effectiveness of this treatment.

Methods & findings

48 patients with CML were included in this study. All patients were previously treated with at least two other drugs. Patients were then treated with ponatinib and followed up for 26.5 months.

After 18 months, 81.8% of patients had fewer signs of cancer in the blood (major molecular response). After 3 years, overall survival was 80.5%.

29 patients experienced serious side effects that affected the heart and blood vessels. These included heart attacks (8.1%), stroke (3.2%), and blood clots (4.8%). These occurred after an average of 5.8 months of treatment.

The bottom line

The study concluded that ponatinib was safe and effective in the treatment of CML in previously treated patients.

The fine print

The study had a small sample size. Larger research is needed to confirm results.

Published By :

Experimental Hematology

Date :

Sep 05, 2018

Original Title :

Ponatinib Evaluation And safety in Real Life CML patients failing ≥2 tyrosine kinase inhibitors: The PEARL observational study.

click here to get personalized updates